TREATMENT BENEFITS ASSOCIATED WITH OPEN LABEL ORAL TREPROSTINIL AFTER CLINICAL WORSENING IN THE PHASE 3 FREEDOM-EV STUDY FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION

Authors
Category Primary study
JournalChest
Year 2019
This article has no abstract
Epistemonikos ID: 51ee74a7b0c94c079351620cf48d9ac6a0edb9c4
First added on: Feb 11, 2025